论文部分内容阅读
目的:分析麝香保心丸联合曲美他嗪治疗老年冠心病心绞痛的疗效及对血浆B型脑钠肽(BNP)水平的影响。方法:选取2010年1月-2015年1月我院收治的老年冠心病心绞痛患者128例作为研究对象,采用随机数字表法将其分为实验组(64例)和对照组(64例),单纯使用曲美他嗪对对照组患者进行治疗,联合使用麝香保心丸和曲美他嗪对实验组患者进行治疗,观察两组患者的临床疗效,比较治疗前后两组血浆BNP水平、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)以及左室射血分数(LVEF),统计两组的不良反应。结果:实验组的治疗总有效率为92.19%,明显高于对照组的62.50%,差异具有统计学意义(P<0.05);治疗后,实验组与对照组血浆BNP、LVEDD、LVESD、LVEF均得到改善,但是实验组改善更明显,差异具有统计学意义(P<0.05);两组不良反应率比较,无统计学差异(P>0.05)。结论:应用麝香保心丸联合曲美他嗪治疗老年冠心病心绞痛的临床疗效显著,且明显降低血浆BNP水平,值得在临床上推广应用。
Objective: To analyze the therapeutic effect of Shexiang Baoxin Pill combined with trimetazidine on angina pectoris of elderly patients with coronary heart disease and its effect on plasma BNP level. Methods: From January 2010 to January 2015, 128 elderly patients with coronary heart disease and angina pectoris admitted to our hospital were selected as experimental subjects. They were divided into experimental group (64 cases) and control group (64 cases) by random number table. The patients in the control group were treated with trimetazidine alone. The patients in the experimental group were treated with Shexiang Baoxin Pill and trimetazidine. The clinical efficacy of the two groups was observed. The levels of plasma BNP, left ventricular diastolic pressure End-stage diameter (LVEDD), left ventricular end-systolic diameter (LVESD) and left ventricular ejection fraction (LVEF). Adverse reactions were calculated in both groups. Results: The total effective rate of the experimental group was 92.19%, which was significantly higher than that of the control group (62.50%), the difference was statistically significant (P <0.05). After treatment, the BNP, LVEDD, LVESD, LVEF (P <0.05). There was no significant difference in adverse reaction rate between the two groups (P> 0.05). Conclusion: The clinical efficacy of Shexiang Baoxin Pill combined with trimetazidine in the treatment of senile coronary heart disease with angina pectoris is significant, and the level of plasma BNP is significantly decreased, which is worth popularizing in clinic.